General information

Announcements(0)

Overview

Manual for Online Meeting

Participant Registration

Abstract Submission (Oral/Poster Presentation)

General information 2

Abstract Submission (Late-Breaking Session)

Program

Sessions

Search presentations

pharm141_en.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

A password that applicants have been notified of is required to view abstracts.<br>If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.<br>We will reply after confirming that you were a participant.<br>Thank you for your understanding.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Profile management

Announcements

Bookmark

Download PDF for print

Timetable

Development of artificial nucleic acids toward oligonucleotide therapeutics for the hypoxia-selectivity and catalytic target RNA cleavage

 In this era, the concept of pharmaceuticals has expanded from small molecule drugs to macromolecule drugs, leading to novel therapeutic strategies such as gene therapy and regenerative medicine. Especially, nucleic acid-based therapeutics have begun to be approved in Japan such as Spinraza®, Onpattro®, and Collategen® in recent years, and further development as a new therapeutic method for incurable diseases is expected. The key factor determining the therapeutic effect of nucleic acid-based therapeutics is how to deliver them to the site of action of target tissues/cells. Due to their low membrane permeability and difficulty in controlling their biodistribution, nucleic acid-based therapeutics is the field where DDS technology is most needed. In recent decades, various nucleic acid and gene delivery technologies such as lipid nanoparticles, micelles, and conjugates have been developed and studied. In this symposium, we will learn how these technologies can overcome the barriers that exist in the process of nucleic acid delivery in vivo, and discuss methodologies for controlling the biodistribution and intracellular trafficking of them. 

Development of DDS technology for nucleic acid drugs and gene therapeutics --From control of pharmacokinetics and intracellular trafficking to therapeutic application--

The 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima)

Presentation Information

[GS02-3]Development of artificial nucleic acids toward oligonucleotide therapeutics for the hypoxia-selectivity and catalytic target RNA cleavage

Password required to view